CLDN18.2 UCAR-T cell therapy

N/A

Report date: 2024/12/20 13:44:04

Base Information

Drug NameCLDN18.2 UCAR-T cell therapy
Drug Alias NameCLDN18.2 UCAR-T
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CLDN18
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesT-Maximum Pharmaceutical (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZhongshan City People'S HospitalT-Maximum Pharmaceutical (Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A